These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 2795879)

  • 21. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Rapid disappearance of M-protein in multiple myeloma complicated by pneumonia during treatment with HLBI].
    Ashihara E; Oku N; Nishio A; Tuji K; Nakamura M
    Rinsho Ketsueki; 1992 Dec; 33(12):1818-23. PubMed ID: 1479692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
    Yoshida S; Takai N; Ono K; Saito T; Tanaka R
    No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells.
    Atzpodien J; Gulati SC
    Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Transfer of interleukin 2-activated lymphocytes].
    Kohgo Y
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 2):2127-34. PubMed ID: 3496856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation.
    Neubauer MA; Benyunes MC; Thompson JA; Bensinger WI; Lindgren CG; Buckner CD; Fefer A
    Bone Marrow Transplant; 1994 Mar; 13(3):311-6. PubMed ID: 7911048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
    Mulé JJ; Shu S; Rosenberg SA
    J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lymphokine-activated killer (LAK) adoptive immunotherapy: optimal method for large-scale LAK induction].
    Nii A; Sone S; Okubo A; Fawzy F; Yanagawa H; Ogura T
    Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1871-6. PubMed ID: 3496049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R; Rosenberg SA
    Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Observation of the effects of LAK/IL-2 therapy combining with Lycium barbarum polysaccharides in the treatment of 75 cancer patients].
    Cao GW; Yang WG; Du P
    Zhonghua Zhong Liu Za Zhi; 1994 Nov; 16(6):428-31. PubMed ID: 7720497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphokine activated killer cells enhance IL-2 prevention of sepsis-related death in a murine model of thermal injury.
    Mendez MV; Molloy RG; O'Riordain DS; Holzheimer RG; Nestor MS; Obando A; Saporoschetz I; Schoof DD; Mannick JA; Rodrick ML
    J Surg Res; 1993 Jun; 54(6):565-70. PubMed ID: 8412066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Augmentation of insulin autoantibodies following interleukin-2 and lymphokine activated killer cell therapy.
    Bergstrom RW; Atkins MB; Mier JW; Palmer JP
    J Clin Lab Immunol; 1990 Apr; 31(4):189-93. PubMed ID: 1967063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cytolytic activity by lymphokines (LAK activity) in chronic myeloid leukemia].
    Cervantes F; Miller JS; McGlave PB
    Med Clin (Barc); 1995 Jun; 105(2):50-3. PubMed ID: 7603094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of patients with malignant pleural effusions due to advanced lung cancer by transfer of autologous LAK cells combined with rIL-2 or rIL-2 alone.
    Li D; Wang Y; Yao X; Shao J; Chen Y; Ba D
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(1):51-5. PubMed ID: 2371266
    [No Abstract]   [Full Text] [Related]  

  • 38. [Evaluation of the cell-mediated immune response after administration of Salmonella antigens in patients with multiple myeloma].
    Indiveri F; Puppo F; Corsini G; Di Benedetto G; Piana A
    Boll Ist Sieroter Milan; 1977 Nov; 56(5):461-6. PubMed ID: 597397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversible bronchial hyperresponsiveness induced by OK-T3/IL-2 administration in a patient with multiple myeloma.
    Rolla G; Bucca C; Brussino L; Massaia M; Bergandi D
    Respiration; 1995; 62(4):228-31. PubMed ID: 8578020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-infiltrating lymphocytes: new therapy, new hopes.
    Fiocchi C; Finke JH
    Gastroenterology; 1990 Feb; 98(2):531-4. PubMed ID: 2295410
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.